MAP Patient Access Conference 2021

Thank you to those who attended our Patient Access Conference on Wednesday 22nd September. It was a successful day with expert speakers from across the industry who shared their opinions, expertise, and passion for patient access.

The programme was delivered around four core market access areas and if you missed out on the day, please find below links to the recordings. We would highly recommend watching to gather expert insights on a range of topics with actionable strategies for accelerating patient access.

Don’t take our word for it….hear from the conference delegates.

"

“Kept me interested throughout the day. Hearing how passionate the patient group representatives are especially regarding the importance of all the NICE methods review. Getting a chance to meet others working in market access was really useful”

“A good selection of speakers, relevant to UK rare disease market access which is exactly my area of interest. Great patient group involvement with practical insights.”

“A good range of speakers and honest tone of the conference. The openness was refreshing as many of these things aren’t shared in a public forum, yet many of us think this; thank you for the candour!”

“Great range of topics and diverse speakers and views. I really enjoyed the conference and am only sorry I couldn’t make it in person.”

"

MAP Patient Access Conference 2021, Delegates

Session 1: Developments in Strategy for Patient Access

Dr Grace Jennings chaired this opening session introducing a range of experts addressing the following topics: the importance of patient engagement throughout the HTA process, using patient registries in HTAs and future development for patient access in new health technologies.

Patient_access_conference_2.jpeg

Speakers

• Dr Grace Jennings, Associate Director MAP Online, MAP
• David Thomas, Co-Chair, Charity Medicines Access Coalition
• Natalie Frankish, Policy and Engagement Manager for Scotland, Genetic Alliance UK
• David Gillen, Global Head Medical Affairs, Menarini Pharma

Request the recording

Session 2: Access to Orphan Medicines

The MAP Policy and Public Affairs team consider how the current and future policy landscape will impact on the market access function for innovative medicines and host an insightful panel discussion with rare disease patient organisations and industry representatives. Panellists reflected on the potential for the NICE methods review, proposed Innovative Medicines Fund and other policy levers to improve access to orphan medicine arrangements.

Patient_access_conference_2.jpeg

Speakers

• Tracey Bowden, Head of Policy, Public Affairs and Communications, MAP
• Gerald Chan, Associate Director, MAP
• Dr Thomas Kenny, CEO Rare Disease Research Partners, MPS Society
• Natalie Frankish, Policy and Engagement Manager for Scotland, Genetic Alliance UK
• Samantha Barber, CEO, Gene People
• Charlie Galvin, General Manager, UK and Ireland, Amicus

Request the recording

Session 3: Innovation Tools

Steve Beard, Chief Consulting Officer, introduced an impressive array of speakers from NHS, NICE and EMIG. They discussed optional and approaches to utilising Real World Evidence lined datasets, the NHS Long Term Plan and what this means for pharma companies and the continued development of digital systems and technology for finding new levels of patient value.

Patient_access_conference_2.jpeg

Speakers

• Steve Beard, Chief Consulting Officer, MAP
• Andi Orlowski, Director of the Health Economics Unit, NHS
• Jasdeep Hayre, Associate Director, Technology Appraisals, NICE
• Darren Spevick, Chair, EMIG Digital Health Special Interest Group

Request the recording

Session 4: Pricing and Policy

This final session of our conference, chaired by Steve Beard, Chief Consulting Officer, MAP who was joined by industry experts, tackled the following topics: VPAS – what you need to know, commercial and managed access in England. This session concluded with a talk from Christian Hill, Chief Executive Officer, and co-founder of MAP, on ATMPs and responding to the new high-cost / high-value drugs.

Patient_access_conference_2.jpeg

Speakers

• Christian Hill, Chief Executive Officer, MAP
• Steve Beard, Chief Consulting Officer, MAP
• David Watson, Director Pricing and Reimbursement, ABPI
• David Thomson, Associate Director, Commercial Liaison, NICE

Request the recording

Session 1: Developments in Strategy for Patient Access

Dr Grace Jennings chaired this opening session introducing a range of experts addressing the following topics: the importance of patient engagement throughout the HTA process, using patient registries in HTAs and future development for patient access in new health technologies.

Speakers

• Dr Grace Jennings, Associate Director MAP Online, MAP
• David Thomas, Co-Chair, Charity Medicines Access Coalition
• Natalie Frankish, Policy and Engagement Manager for Scotland, Genetic Alliance UK
• David Gillen, Global Head Medical Affairs, Menarini Pharma

Request the recording

Session 2: Access to Orphan Medicines

The MAP Policy and Public Affairs team consider how the current and future policy landscape will impact on the market access function for innovative medicines and host an insightful panel discussion with rare disease patient organisations and industry representatives. Panellists reflected on the potential for the NICE methods review, proposed Innovative Medicines Fund and other policy levers to improve access to orphan medicine arrangements.

Speakers

• Tracey Bowden, Head of Policy, Public Affairs and Communications, MAP
• Gerald Chan, Associate Director, MAP
• Dr Thomas Kenny, CEO Rare Disease Research Partners, MPS Society
• Natalie Frankish, Policy and Engagement Manager for Scotland, Genetic Alliance UK
• Samantha Barber, CEO, Gene People
• Charlie Galvin, General Manager, UK and Ireland, Amicus

Request the recording

Session 3: Innovation Tools

Steve Beard, Chief Consulting Officer, introduced an impressive array of speakers from NHS, NICE and EMIG. They discussed optional and approaches to utilising Real World Evidence lined datasets, the NHS Long Term Plan and what this means for pharma companies and the continued development of digital systems and technology for finding new levels of patient value.

Speakers

• Steve Beard, Chief Consulting Officer, MAP
• Andi Orlowski, Director of the Health Economics Unit, NHS
• Jasdeep Hayre, Associate Director, Technology Appraisals, NICE
• Darren Spevick, Chair, EMIG Digital Health Special Interest Group

Request the recording

Session 4: Pricing and Policy

This final session of our conference, chaired by Steve Beard, Chief Consulting Officer, MAP who was joined by industry experts, tackled the following topics: VPAS – what you need to know, commercial and managed access in England. This session concluded with a talk from Christian Hill, Chief Executive Officer, and co-founder of MAP, on ATMPs and responding to the new high-cost / high-value drugs.

Speakers

• Christian Hill, Chief Executive Officer, MAP
• Steve Beard, Chief Consulting Officer, MAP
• David Watson, Director Pricing and Reimbursement, ABPI
• David Thomson, Associate Director, Commercial Liaison, NICE

Request the recording

Developments in
strategy and HTA

  • The importance of patient engagement throughout the HTA process

  • Using patient registries in HTAs

  • Appraisal process of medical devices compared with drugs

  • Health economic modelling of digital apps

  • Access to Orphan Medicines: Developing policies for the future

Innovation tools

  • Approaches to utilising Real World Evidence (RWE)

  • Using analytics and big data to gain competitive advantage in Market Access

  • Collaborative working and horizon scanning

  • Harnessing digital systems and technology to find new levels of patient value

Pricing and policy

  • VPAS – what you need to know

  • Updates on The Commercial Framework

  • Advanced Therapy Medicinal Products – Responding to new high cost/high value drugs

  • The NHS Long Term Plan and what this actually means for pharma companies

Who should attend?

This conference should be attended by representatives from UK, European and global pharmaceutical, biotech, life science and MedTech industries, as well as patient organisations and patient groups.

The job functions that will benefit most include:

Heads of Market Access

Country Managers

Health Economists

Commercial Directors

Marketing Directors

Managing Directors

Chief Executives

Medical Directors

Policy Officers/Executives

Policy Advisors

Heads of Market Access

Country Managers

Health Economists

Commercial Directors

Marketing Directors

Managing Directors

Chief Executives

Medical Directors

Policy Officers/Executives

Policy Advisors

Expert speaker faculty

Andi Orlowski

Director of the Health Economics Unit (NHS)

Charlie Galvin

General Manager, UK and Ireland, Amicus and Board Member, Association of British Pharmaceutical Industry

Christian Hill

CEO, MAP BioPharma

Darren Spevick

Head of Europe, TSP and Chair of the EMIG Digital Health Special Interest Group

David Gillen

Global Head of Medical Affairs and Safety, Menarini Pharma

David Thomas

Co-Chair, Charity Medicines Access Coalition

David Watson

Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI)

Jasdeep Hayre

Associate Director, Technology Appraisals, NICE

Natalie Frankish

Policy and Engagement Manager, Genetic Alliance Virtual


Dr Thomas Kenny

CEO Rare Disease Research Partners, MPS Society

Tracey Bowden

Head of Policy and Public Affairs, MAP BioPharma

Samantha Barber

CEO, Gene People

Exhibitors

NIHRIO_RGB_logo_outlined_COL

We are an independent horizon scanning centre based at Newcastle University in the UK. We use advanced horizon scanning techniques to detect new health innovations and track them; from patent-to-patient.

NICE provide UK national guidance for the NHS through their NICE technology appraisal (TA) and highly specialised technology (HST) process. NIHRIO is industry’s gateway to NICE, notifying NICE about new or repurposed drugs 3 years before UK license. This early notification allows NICE to provide new technology guidance as close to the license date as possible, ensuring efficient UK market access.

O4 research

O4 Research is a UK/Ireland based provider of innovative, sector leading clinical trial services and ‘On & Off’ site management solutions. For over a decade we have successfully delivered full and functional services for Top 20 Pharma, biotech and medical device clients across Clinical Phases II-IV and RWE studies. We understand the value of RWE and its role in the development of new healthcare interventions. Our scientific expertise, combined with advances in data acquisition, mean we are ideally placed to help you deliver a bespoke solution for timely and compelling evidence generation. We take the complex and make it simple.

Eucope LOGO-RZ_4c-scaled

EUCOPE is Europe’s trade body for small to medium-sized innovative companies working in the field of pharmaceuticals and medical technologies.

Based in Brussels, EUCOPE gives voice to more than 900 research-oriented innovative companies and associations active in research, development of pharmaceuticals, biotechnologies and medical devices. Many of our members are developing therapeutic solutions for persons living with a rare disease, who had little to no treatment available just a few years ago.

NIHRIO_RGB_logo_outlined_COL

We are an independent horizon scanning centre based at Newcastle University in the UK. We use advanced horizon scanning techniques to detect new health innovations and track them; from patent-to-patient.

NICE provide UK national guidance for the NHS through their NICE technology appraisal (TA) and highly specialised technology (HST) process. NIHRIO is industry’s gateway to NICE, notifying NICE about new or repurposed drugs 3 years before UK license. This early notification allows NICE to provide new technology guidance as close to the license date as possible, ensuring efficient UK market access.

O4 research

O4 Research is a UK/Ireland based provider of innovative, sector leading clinical trial services and ‘On & Off’ site management solutions. For over a decade we have successfully delivered full and functional services for Top 20 Pharma, biotech and medical device clients across Clinical Phases II-IV and RWE studies. We understand the value of RWE and its role in the development of new healthcare interventions. Our scientific expertise, combined with advances in data acquisition, mean we are ideally placed to help you deliver a bespoke solution for timely and compelling evidence generation. We take the complex and make it simple.

Eucope LOGO-RZ_4c-scaled

EUCOPE is Europe’s trade body for small to medium-sized innovative companies working in the field of pharmaceuticals and medical technologies.

Based in Brussels, EUCOPE gives voice to more than 900 research-oriented innovative companies and associations active in research, development of pharmaceuticals, biotechnologies and medical devices. Many of our members are developing therapeutic solutions for persons living with a rare disease, who had little to no treatment available just a few years ago.

Agenda

Wednesday 22nd September - All times in BST. 

Session One
08:30 – Morning coffee & registration
09:00 – Welcome to Patient Access 2021. Introductions and scene setting – Christian Hill, CEO MAP BioPharma

Developments in strategy for Patient Access
09:15 – The importance of patient engagement throughout the HTA process – David Thomas, Co-Chair, Charity Medicines Access Coalition and Natalie Frankish, Policy and Engagement Manager for Scotland, Genetic Alliance UK

09:45 – Using patient registries in HTAs – David Gillen, Global Head of Medical Affairs and Safety, Menarini Pharma

10:15 – Future development for Patient Access in new health technologies – Dr Grace Jennings, Head of MAP Online, MAP BioPharma

Break
10:45 – Refreshments & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE

Session Two
11:15 – Access to Orphan Medicines: Developing policies for the future – Policy and Public Affairs Team, MAP BioPharma

11:45 – Panel Discussion: Led by MAP’s Policy and Public Affairs team, this interactive session will bring together experts to consider challenges with and solutions for the appraisal of medicines for rare diseases.

Panellists will reflect on the potential for the NICE methods review, proposed Innovative Medicines Fund and other policy levers to improve access to orphan medicines arrangements. Our panel includes:

Dr Thomas Kenny, CEO Rare Disease Research Partners, MPS Society
Natalie Frankish, Policy and Engagement Manager, Genetic Alliance Virtual
Samantha Barber, CEO, Gene People
Charlie Galvin, General Manager, UK and Ireland, Amicus and Board Member, Association of British Pharmaceutical Industry
Tracey Bowden, Head of Policy and Public Affairs, MAP BioPharma

Break
12:30 – Lunch & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE

Session Three - Innovation tools
13:30 – Approaches to utilising Real World Evidence (RWE) – Andi Orlowski, Director of the Health Economics Unit (NHS)

14:00 – Collaborative working and Horizon Scanning – The NHS Long Term Plan and what this actually means for pharma companies -  Jasdeep Hayre, Associate Director, Technology Appraisals, NICE

14:30 – Harnessing digital systems and technology to find new levels of patient value – Darren Spevick, Head of Europe, TSP and Chair of the EMIG Digital Health Special Interest Group

Break
15:00 – Refreshments & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE

Session Four - Pricing and policy
15:30 – VPAS – what you need to know – David Watson, Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI)

16:00 – Commercial and Managed Access in England – David Thomson, Associate Director – Commercial Liaison (PASLU), NICE

16:30 – Advanced Therapy Medicinal Products – Responding to new high cost/high value drugs
Outputs from ‘meet the expert’ sessions across Europe in 2020 – Christian Hill, Chief Executive Officer, MAP

17:00 – Conference Close – Networking Drinks Reception

Book Virtual Viewing Tickets

Note: This is an online viewing option for our London conference. A live stream broadcast will run throughout the day. The live link will be emailed to registered delegates 48 hours before the start of the event.
All registered attendees will have post event access to on-demand videos of each speaker session.

CareersTerms and ConditionsComplaints ProcedurePrivacy PolicyCookie Policy

Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.

MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom

 +44 (0) 1480 832360

 enquiries@mapbiopharma.com

MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281

VAT Group Registration Number:
GB 292 8576 52